trending Market Intelligence /marketintelligence/en/news-insights/trending/loCH69m_LU9tK-Ury9DAUw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Mereo, Oncologie sign $4M upfront licensing deal for ovarian cancer drug

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Mereo, Oncologie sign $4M upfront licensing deal for ovarian cancer drug

Mereo BioPharma Group PLC has signed a licensing agreement with Oncologie Inc. for the development of navicixizumab, which is under evaluation in early clinical trials for treating ovarian cancer.

Oncologie, a privately held biotechnology company based in Waltham, Mass., will receive a worldwide license to develop and commercialize navicixizumab through the deal. Mereo will receive an upfront payment of $4 million, plus an additional payment of $2 million based on a certain chemistry, manufacturing and controls milestone.

Additional payments of up to $300 million will be offered to Mereo based on clinical, regulatory and commercial milestones, plus royalties based on global sales.

U.K.-based Mereo acquired navicixizumab through the 2019 acquisition of OncoMed Pharmaceuticals Inc. The therapy was granted a fast-track designation by the U.S. Food and Drug Administration for a certain type of ovarian cancer in October 2019.